http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-116905-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c1ee19e6efdf91c1bf88bde9e9845ef |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-443 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D207-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12 |
| filingDate | 2019-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6632bb2fec5cdba8151fecb6b93a0f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc17392ca7cb3999c32ec3af595cd211 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c9eceffd0646b03ff099e436ad8434a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5186da443a6553f547d2d87edd47ba3c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f421b4cab15437712fd9f1d0ba2f59b2 |
| publicationDate | 2021-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-116905-A1 |
| titleOfInvention | PYRROLIDINE-2-CARBOXYL ACID DERIVATIVES TO TREAT PAIN AND PAIN-RELATED CONDITIONS |
| abstract | This refers to compounds that show dual pharmacological activity with respect to the a2d voltage-gated calcium channel (VGCC) subunit, especially the a2d-1 voltage-gated calcium channel subunit, and the m-opioid receptor (MOR or mu-opioid). The present also refers to the process for the preparation of said compounds, as well as to the compositions comprising them and their use as medicaments. Claim 1: A compound of general formula (1), where: W¹ is -O-, -NRᵃ or -CH₂-; Rᵃ is a hydrogen atom or a branched or unbranched C₁₋₆ alkyl radical; n and m are independently of each other 0 or 1; R¹, R² and R⁴ are independently of each other a hydrogen atom; a branched or unbranched C₁₋₆ alkyl radical; a halogen atom; a C (O) H radical; a branched or unbranched C₁₋₆ alkoxy radical; a radical -NRᵇRᶜ; a -CN radical; a hydroxyl radical; or a C₁₋₆ haloalkyl radical; Rᵇ and Rᶜ are independently of each other a hydrogen atom or a branched or unbranched C₁₋₆ alkyl radical; R³ is selected from: the compounds of formula (2) and (3); W² is -C (O) -, -CH₂- or a bond; A is C or N; the dashed line represents an optional double bond; R³ᵃ and R³ᵇ are independently of each other a hydrogen atom or a branched or unbranched C₁₋₆ alkyl radical; or R³ᵃ and R³ᵇ together with the bridging nitrogen form a 4-, 5- or 6-membered heterocycloalkyl radical optionally containing an additional heteroatom selected from N, O and S optionally substituted with a branched or unbranched C₁₋₆ alkyl radical or an alkoxy radical C₁₋₆ branched or unbranched; R³ᶜ is a hydrogen atom; a halogen atom; a hydroxyl radical; a branched or unbranched C₁₋₆ alkyl radical; a branched or unbranched C₁₋₆ alkoxy radical; a -CN radical; a C₁₋₆ haloalkyl radical; or a radical -NR³ᶜR³ᵈ; R³ᵈ and R³ᵉ are independently of each other a hydrogen atom or a branched or unbranched C₁₋₆ alkyl radical; R⁵ is a hydrogen atom or a radical -C (O) R⁵ᵃ; R⁵ᵃ is a hydrogen atom; a branched or unbranched C₁₋₆ alkyl radical; a branched or unbranched C₁₋₆ alkoxy radical; a radical - (CH₂) ʳ-NR⁵ᵇR⁵ᶜ; a radical -OCH (CH₃) OC (O) CH (CH₃) ₂; or a radical -NR⁵ᵍ- (CH₂) ₛ-CH (R⁵ᶠ) -NR⁵ᵉR⁵ᵈ; r is 1, 2, 3, 4, 5, or 6; s is 1, 2, 3, 4, 5, or 6; R⁵ᵇ, R⁵ᶜ, R⁵ᵈ, R⁵ᵉ, R⁵ᵍ are independently of one another a hydrogen atom; or a branched or unbranched C₁₋₆ alkyl radical; R⁵ᶠ is a hydrogen atom or a radical -COR⁵ʰ; R⁵ʰ is a hydroxyl radical or a branched or unbranched C₁₋₆ alkyl radical; R⁶ is a radical -C (O) R⁶ᵃ; an optionally substituted 5- or 6-membered heteroaryl ring containing at least one heteroatom selected from N, O, and S; R⁶ᵃ is a hydroxyl radical, a branched or unbranched C₁₋₆ alkoxy radical; a radical - (CH₂) ₜ-NR⁶ᵇR⁶ᶜ; a radical -OCH (CH₃) OC (O) CH (CH₃) ₂; or a radical -NR⁶ᵍ- (CH₂) ᵛCH (R⁶ᶠ) -NR⁶ᵉR⁶ᵈ; t is 1, 2, 3, 4, 5, or 6; v is 1, 2, 3, 4, 5, or 6; R⁶ᵇ, R⁶ᶜ, R⁶ᵈ, R⁶ᵉ, R⁶ᵍ are independently of one another a hydrogen atom; or a branched or unbranched C₁₋₆ alkyl radical; R⁶ᶠ is a hydrogen atom or a radical -COR⁶ʰ; R⁶ʰ is a hydroxyl radical or a branched or unbranched C₁₋₆ alkyl radical; or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof. |
| priorityDate | 2018-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 31.